Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Amgen    AMGN

AMGEN (AMGN)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Amgen, Inc. : A Tribute to George Rathmann, Amgen's Founding CEO (1927-2012)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/24/2012 | 04:55am CET

THOUSAND OAKS, Calif., April 23, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that George Rathmann, founding CEO of Amgen from 1980 to 1988 and board chairman until 1990, has passed away.

Recruited by Bill Bowes, one of Amgen's founders, Rathmann possessed the kind of passion and charisma that helped build the company and attract world-class scientific talent. Regarded as one of the founding fathers of biotechnology, George had the vision to see how biotechnology could transform the practice of medicine with the mix of business and science to bring that vision to life. One of Rathmann's chief accomplishments was finding the funds Amgen needed during its start-up years. Nicknamed the "Golden Throat" by friends who admired his persuasiveness, he secured venture capital, built revenue streams through partnerships, and guided Amgen through its first public offerings.

"George Rathmann was a biotechnology giant and we were privileged to have him as our first CEO. George's vision and values are as alive today at Amgen as they were when he led the Company," said Kevin Sharer, Chairman and CEO of Amgen. "Bob Bradway, our next CEO, and I both share George's commitment to patients and conviction that being science-based is the best foundation for innovation in biotechnology."

Through the years, Amgen has continued to recognize the significant impact Rathmann made on the Company. In 2004, a full-size sculpture of Rathmann was dedicated on Amgen's campus in recognition of his leadership. In 2005, Amgen created the annual George B. Rathmann Award, the company's highest honor, to recognize staff members who exemplify Amgen's standards of excellence to advance Amgen's mission to serve patients.

Rathmann was recognized as BIO's CEO of the year in 1987 and 1988. Upon leaving Amgen, Rathmann became CEO and chairman of Seattle-based biotech ICOS Corporation (later acquired by Eli Lilly). He later served as CEO and chairman of genomics company Hyseq, Inc.

About Amgen
Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe, effective medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and vital medicines, visit www.amgen.com. Follow us on www.twitter.com/amgen.

CONTACT: Amgen, Thousand Oaks
Christine Regan, 805-447-5476 (media)

(Logo: http://photos.prnewswire.com/prnh/20081015/AMGENLOGO)

SOURCE Amgen


© PRNewswire 2012
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on AMGEN
02/19Rare Haematology Market Trend to 2025 Profiling PRA Health Sciences, Bayer He..
AQ
02/16NOVARTIS : readies to auction U.S. generic pills business - sources
RE
02/15AMGEN : Results From Phase 3 XGEVA® Denosumab Study In Patients With Multiple My..
AQ
02/15AMGEN : Researchers at Amgen Have Reported New Data on Oligopeptides (Rapid scre..
AQ
02/14AMGEN : Announces FDA Advisory Committee Meeting To Review Potential New Use Of ..
PU
02/14+50% CAGR TO BE ACHIEVED BY BIOSIMIL : Global Biosimilars Market – Know In..
AQ
02/14GLOBAL EYE CANCER MARKET REPORT WITH : Global Eye Cancer Market - Global Industr..
AQ
02/14AMGEN : ex-dividend day
FA
02/12AMGEN : Today’s Research Reports on Trending Tickers: Amgen and Celgene
AC
02/12American College of Rheumatology recommends biosimilars for rheumatic disease
AQ
More news
News from SeekingAlpha
01:54aAGENUS : Positioned To Rapidly Enhance Shareholder Value 
02/19Healthcare In Transition 
02/19VALUATION DASHBOARD : Healthcare - Update 
02/173 THINGS IN BIOTECH YOU SHOULD LEARN : February 17, 2018 
02/15FDA issues draft industry guidance for early-stage Alzheimer's disease